<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181401</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT No. 2010-019347-18</org_study_id>
    <nct_id>NCT01181401</nct_id>
  </id_info>
  <brief_title>InductionChemo-Radio-Antibody-Treatment</brief_title>
  <acronym>ICRAT</acronym>
  <official_title>Randomized Phase II Study of Two Different Regimens of TPF Induction Chemotherapy Regimen Followed by Radiation Therapy Plus Cetuximab (TPF-CET-HART) vs. HART and Cis-platinum, 5-FU (PF-HART) in Patients With Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, randomized, Phase II-study to evaluate the efficacy of a standard-TPF
      induction chemotherapy (IC) and an alternative TPF induction chemotherapy followed by
      radio-antibody-therapy, in patients with unresectable LA-SCC of the HN region
      (oro-hypopharynx carcinoma, cancer of the oral cavity).

      The primary objective of the study is to assess the feasibility of an experimental
      'fractionated' TPF regimen compared to a current standard TPF regimen.

      Composite endpoint of compliance and feasibility in terms of

        -  response (RECIST1.1) and

        -  hematological acute toxicity (CTCAE v.4.02)

        -  on time application of RAT following an experimental or standard TPF IC.

      Secondary endpoints are

        -  Treatment intensity achieved

        -  Toxicity (according to CTCAE v.4.02)

        -  Response rates after completion of induction chemotherapy and after completion of entire
           protocol treatment (RECIST1.1)

        -  Survival (progression-free, metastasis-free, recurrence-free, overall) 1 year after
           randomisation

        -  Quality of life according to EORTC QoL C30 &amp; HN35

      The study will be conducted at 5-6 investigational sites in Germany recruiting 90 patients in
      total. Eligible patients will have a diagnosis of histologically confirmed SSC of the HN.
      Patients will receive one of 2 different regimens of TPF IC followed by cetuximab together
      with radiotherapy (RAT) or a standard radiochemotherapy(RCT) regimen.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of an experimental 'fractionated' TPF regimen compared to a current standard TPF regimen.</measure>
    <time_frame>August 2010- December 2012</time_frame>
    <description>acute hematological toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival and late morbidity</measure>
    <time_frame>1 year</time_frame>
    <description>All adequate items illustrating acute toxicity and late morbidity, in particular by hematological measures until one year after treatment (according to NCI-CTCAE v.4.02) Survival (progression-free, metastases-free, recurrence-free, Overall survival) after 1 year Response rates after TPF IC (RECIST1.1) Response rates after completion of multimodal treatment (see follow-up for scheduling RECIST1.1) Efficacy in relation to HPV status (p16 IHC) Quality of life according to EORTC QLC-30 &amp; HN35</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Squamous Cell Carcinoma of the Head</condition>
  <condition>Squamous Cell Carcinoma of the Neck</condition>
  <arm_group>
    <arm_group_label>TPF standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TPF version 1 (standard)
Induction chemotherapy:
Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 every 21 days for 3 cycles
Antibody therapy with:
cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
RTX: HART (72 Gy), IMRT or 3D-conformal techniques</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TPF experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TPF version 2 (experimental)
Induction chemotherapy:
Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles
Antibody therapy with:
cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
RTX: HART (72 Gy), IMRT or 3D-conformal techniques</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard RCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard RCT:
HART (72 Gy), IMRT or 3D-conformal techniques
with concurrent chemotherapy: Cis-platinum 30 mg/m2 once weekly d 1, 8, 15, 22, 29, 36 5-FU 600mg/m² /24h c.i. d 1-5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPF induction chemotherapy</intervention_name>
    <description>Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX</description>
    <arm_group_label>TPF standard</arm_group_label>
    <other_name>Docetaxel (Taxotere)</other_name>
    <other_name>Cisplatin</other_name>
    <other_name>5-Flurouracil</other_name>
    <other_name>Cetuximab (Erbitux)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPF experimental</intervention_name>
    <description>Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX</description>
    <arm_group_label>TPF experimental</arm_group_label>
    <other_name>Docetaxel (Taxotere)</other_name>
    <other_name>Cisplatin</other_name>
    <other_name>5-Flurouracil</other_name>
    <other_name>Certuximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard Radiochemotherapy (HART)</intervention_name>
    <description>Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy</description>
    <arm_group_label>Standard RCT</arm_group_label>
    <other_name>Cis-platinum</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven unresectable SCC of the oral cavity, oropharynx and hypopharynx
             (stage IVA &amp; IVB)

          -  Written and signed informed consent

          -  Karnofsky PS &gt; 70 %

          -  Age ≥ 18 years

          -  Curative treatment intent

          -  Adequate bone marrow, hepatic and renal functions as evidenced by the following:

        Hematology (Bone marrow):

          -  Neutrophils &gt; 2.0 109/L

          -  Platelets &gt; 100 x 109/L

          -  Hemoglobin &gt; 10 g/dL

        Hepatic function:

          -  Total serum bilirubin &lt; 1 time the UNL of the participating center

          -  ASAT (SGOT) and ALAT (SGPT) &lt; 2.5 x UNL

          -  Alkaline phosphatase &lt; 5 x UNL

        Renal function :

          -  serum creatinine (SC) &lt; 120 µmol/L (1.4 mg/dl);

          -  if values are &gt; 120 µmol/L, the creatinine clearance should be &gt; 60 ml/min (actual or
             calculated by the Cockcroft-Gault method as follows :

        weight (kg) x (140 - age) --------------------------------- K x serum creatinine

        serum creatinine in mg/dL: K = 72 in man K = 85 in woman serum creatinine in µmol/L: K =
        0.814 in man K = 0.96 in woman

        • If of childbearing potential, willingness to use effective contraceptive method for the
        study duration and 2 months post-dosing.

        All patients require:

          -  dental examination and appropriate dental preservation if needed 1 week prior to the
             beginning of radiotherapy,

          -  gastric feeding tube and Portal-catheter.

        Exclusion Criteria:

          -  Other neoplasia within the past 5 years with the exception of a controlled skin cancer
             or &quot;in situ&quot; cervix cancer

          -  Unknown primary (CUP), nasopharynx, laryngeal or salivary gland cancer

          -  Distant metastatic disease (M1)

          -  Serious co-morbidity, e.g. arteriosclerosis with apoplexy, recent myocardial
             infarction, high-grade carotid stenoses, unstable cardiac disease despite treatment,
             congestive heart failure NYHA grade 3 and 4, insulin-dependent diabetes mellitus,
             uncontrolled hypertension, liver cirrhosis (Quick &lt; 75%, total protein &lt;3.0 g/dl,
             bilirubin &gt;2mg/ml) or kidney insufficiency (creatinine &gt;1.4 mg/ml, the creatinine
             clearance should be &gt; 60 ml/min)

          -  patients with ASAT or ALAT &gt; 2.5 UNL associated with alkaline phosphatase &gt; 5 UNL are
             not eligible for the study

          -  Known HIV-infection

          -  Pregnancy or lactation

          -  Women of child-bearing potential with unclear contraception

          -  Previous treatment of the disease with chemotherapy, radiotherapy, EGFR-targeting
             agents or surgery exceeding biopsy in head and neck

          -  Concurrent treatment with other experimental drugs or participation in another
             clinical trial with any investigational drug within 30 days prior to study screening

          -  Social situations that limit compliance with study requirements

          -  Deficient dental preservation status or not accomplished wound healing

          -  Legal incapacity

          -  Prior accommodation in an institution under officially or judicially orders (§ 40 1 p.
             3 No. 4 AMG)

          -  Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria
             (NCI-CTC) grade 2 and/or ototoxicity grade 2, except if due to trauma or mechanical
             impairment due to tumor mass

          -  Known allergic/hypersensitivity reaction to any of the components of the treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Budach, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Universitaetsmedizin Berlin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carmen Stromberger, MD</last_name>
    <phone>0049 (0) 30 450</phone>
    <phone_ext>657105</phone_ext>
    <email>carmen.stromberger@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylvia Blass</last_name>
    <phone>0049 (0) 30 450 527 318</phone>
    <email>sylvia.blass@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Universitaetsmedizin Berlin, CVK, CBF</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Stromberger, MD</last_name>
      <phone>0049 (0) 30 450</phone>
      <phone_ext>657105</phone_ext>
      <email>carmen.stromberger@charite.de</email>
    </contact>
    <investigator>
      <last_name>Carmen Stromberger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan-Dirk Raguse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eva-Tessina Becker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrich Keilholz, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lutz Moser, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heidi Olze, MD, PD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rainald Knecht, MD, PhD</last_name>
      <phone>0049 (0) 40 / 74105</phone>
      <phone_ext>2360</phone_ext>
      <email>r.knecht@uke.de</email>
    </contact>
    <investigator>
      <last_name>Philippe Schafhausen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cordula Petersen, MD, PD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Viktor Grünwald Grünwald, MD, PD</last_name>
      <phone>0049 (0) 511 5324077 / 9196</phone>
      <email>Gruenwald.Viktor@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Viktor Grünwald, MD, PD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rita Engenhart-Cabillic, MD, PD</last_name>
      <phone>0049 (0) 6421 58-66434</phone>
      <email>engenhar@med.uni-marburg.de</email>
    </contact>
    <investigator>
      <last_name>Rita Engenhart-Cabillic, MD, PD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oliver Koelbel, MD, PD</last_name>
      <phone>0049 (0941) 944 9410</phone>
      <email>oliver.koelbl@klinik.uni-regensburg.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Koelbl, MD, PD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hermann Hilber, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1695-704.</citation>
    <PMID>17960012</PMID>
  </results_reference>
  <results_reference>
    <citation>Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007 Oct 25;357(17):1705-15.</citation>
    <PMID>17960013</PMID>
  </results_reference>
  <results_reference>
    <citation>Haddad R, Colevas AD, Tishler R, Busse P, Goguen L, Sullivan C, Norris CM, Lake-Willcutt B, Case MA, Costello R, Posner M. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Cancer. 2003 Jan 15;97(2):412-8.</citation>
    <PMID>12518365</PMID>
  </results_reference>
  <results_reference>
    <citation>Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10. Erratum in: Lancet Oncol. 2010 Jan;11(1):14.</citation>
    <PMID>19897418</PMID>
  </results_reference>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <last_update_submitted>August 26, 2010</last_update_submitted>
  <last_update_submitted_qc>August 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2010</last_update_posted>
  <responsible_party>
    <name_title>Volker Budach, Principal Investigator</name_title>
    <organization>Charité Universitaetsmedizin Berlin</organization>
  </responsible_party>
  <keyword>induction chemotherapy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>locally advanced head neck tumor</keyword>
  <keyword>toxicity</keyword>
  <keyword>LA SCCHN</keyword>
  <keyword>Unresectable squamous cell cancer of the head and neck,</keyword>
  <keyword>Stage IV (UICC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

